Affordable Access

Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries.

Authors
  • Pires, Nuno M M
  • Eefting, Daniel
  • de Vries, Margreet R
  • Quax, Paul H A
  • Jukema, J Wouter
Type
Published Article
Journal
Heart
Publisher
BMJ
Publication Date
Aug 01, 2007
Volume
93
Issue
8
Pages
922–927
Identifiers
PMID: 17449502
Source
Medline
License
Unknown

Abstract

Sirolimus and paclitaxel are effective in preventing restenosis. Sirolimus has no significant effect on arterial disease. In contrast, paclitaxel at high concentration demonstrated adverse vascular pathology and transcriptional responses, suggesting a narrower therapeutic range of this potent drug. Since the use of overlapping stents is becoming more common in DES technology, this factor is important, given that higher dosages of paclitaxel may lead to increased apoptosis in the vessel wall and, consequently, to a more unstable phenotype of the pre-existing atherosclerotic lesion.

Report this publication

Statistics

Seen <100 times